Literature DB >> 24872583

Progression from IgD+ IgM+ to isotype-switched B cells is site specific during coronavirus-induced encephalomyelitis.

Timothy W Phares1, Krista D DiSano2, Stephen A Stohlman1, Cornelia C Bergmann3.   

Abstract

UNLABELLED: Various infections in the central nervous system (CNS) trigger B cell accumulation; however, the relative dynamics between viral replication and alterations in distinct B cell subsets are largely unknown. Using a glia-tropic coronavirus infection, which is initiated in the brain but rapidly spreads to and predominantly persists in the spinal cord, this study characterizes longitudinal changes in B cell subsets at both infected anatomical sites. The phase of T cell-dependent, antibody-independent control of infectious virus was associated with a similar recruitment of naive/early-activated IgD(+) IgM(+) B cells into both the brain and spinal cord. This population was progressively replaced by CD138(-) IgD(-) IgM(+) B cells, isotype-switched CD138(-) IgD(-) IgM(-) memory B cells (B(mem)), and CD138(+) antibody-secreting cells (ASC). A more rapid transition to B(mem) and ASC in spinal cord than in brain was associated with higher levels of persisting viral RNA and transcripts encoding factors promoting B cell migration, differentiation, and survival. The results demonstrate that naive/early-activated B cells are recruited early during coronavirus CNS infection but are subsequently replaced by more differentiated B cells. Furthermore, viral persistence, even at low levels, is a driving force for accumulation of isotype-switched B(mem) and ASC. IMPORTANCE: Acute and chronic human CNS infections are associated with an accumulation of heterogeneous B cell subsets; however, their influence on viral load and disease is unclear. Using a glia-tropic coronavirus model, we demonstrate that the accumulation of B cells ranging from early-activated to isotype-switched differentiation stages is both temporally and spatially orchestrated. Acutely infected brains and spinal cords indiscriminately recruit a homogeneous population of early-activated B cells, which is progressively replaced by diverse, more differentiated subsets. The latter process is accelerated by elevated proinflammatory responses associated with viral persistence. The results imply that early-recruited B cells do not have antiviral function but may contribute to the inflammatory environment or act as antigen-presenting cells. Moreover, CNS viral persistence is a driving force promoting differentiated B cells with protective potential.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24872583      PMCID: PMC4136247          DOI: 10.1128/JVI.00861-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  98 in total

1.  Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid.

Authors:  Gregory P Owens; Alanna M Ritchie; Mark P Burgoon; R Anthony Williamson; John R Corboy; Donald H Gilden
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

Review 2.  Control systems and decision making for antibody production.

Authors:  Christopher C Goodnow; Carola G Vinuesa; Katrina L Randall; Fabienne Mackay; Robert Brink
Journal:  Nat Immunol       Date:  2010-07-20       Impact factor: 25.606

3.  TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts.

Authors:  Claudia Bossen; Teresa G Cachero; Aubry Tardivel; Karine Ingold; Laure Willen; Max Dobles; Martin L Scott; Aris Maquelin; Elodie Belnoue; Claire-Anne Siegrist; Stéphane Chevrier; Hans Acha-Orbea; Helen Leung; Fabienne Mackay; Jürg Tschopp; Pascal Schneider
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

4.  Alphavirus-induced encephalomyelitis: antibody-secreting cells and viral clearance from the nervous system.

Authors:  Talibah U Metcalf; Diane E Griffin
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

Review 5.  Germinal centers.

Authors:  I C MacLennan
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

Review 6.  Lymphoid chemokines in the CNS.

Authors:  Stephen J Lalor; Benjamin M Segal
Journal:  J Neuroimmunol       Date:  2010-06-01       Impact factor: 3.478

Review 7.  Homing of antibody secreting cells.

Authors:  Jason G Cyster
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

8.  Finding a way out: lymphocyte egress from lymphoid organs.

Authors:  Susan R Schwab; Jason G Cyster
Journal:  Nat Immunol       Date:  2007-12       Impact factor: 25.606

Review 9.  Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.

Authors:  Kenji Chiba; Hirofumi Matsuyuki; Yasuhiro Maeda; Kunio Sugahara
Journal:  Cell Mol Immunol       Date:  2006-02       Impact factor: 11.530

10.  APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells.

Authors:  Elodie Belnoue; Maria Pihlgren; Tracy L McGaha; Chantal Tougne; Anne-Françoise Rochat; Claudia Bossen; Pascal Schneider; Bertrand Huard; Paul-Henri Lambert; Claire-Anne Siegrist
Journal:  Blood       Date:  2008-01-07       Impact factor: 22.113

View more
  13 in total

1.  Protective Humoral Immunity in the Central Nervous System Requires Peripheral CD19-Dependent Germinal Center Formation following Coronavirus Encephalomyelitis.

Authors:  Jeffrey R Atkinson; Cornelia C Bergmann
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

2.  Differential Regulation of Self-reactive CD4+ T Cells in Cervical Lymph Nodes and Central Nervous System during Viral Encephalomyelitis.

Authors:  Carine Savarin; Cornelia C Bergmann; David R Hinton; Stephen A Stohlman
Journal:  Front Immunol       Date:  2016-09-21       Impact factor: 7.561

3.  Interleukin-10 is a critical regulator of white matter lesion containment following viral induced demyelination.

Authors:  Shweta S Puntambekar; David R Hinton; Xinghua Yin; Carine Savarin; Cornelia C Bergmann; Bruce D Trapp; Stephen A Stohlman
Journal:  Glia       Date:  2015-06-30       Impact factor: 7.452

4.  An optimized method for enumerating CNS derived memory B cells during viral-induced inflammation.

Authors:  Krista D DiSano; Stephen A Stohlman; Cornelia C Bergmann
Journal:  J Neurosci Methods       Date:  2017-05-08       Impact factor: 2.390

5.  Central Nervous System Inflammatory Aggregates in the Theiler's Virus Model of Progressive Multiple Sclerosis.

Authors:  Krista D DiSano; Darlene B Royce; Francesca Gilli; Andrew R Pachner
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

Review 6.  B Cells and Microbiota in Autoimmunity.

Authors:  María Botía-Sánchez; Marta E Alarcón-Riquelme; Georgina Galicia
Journal:  Int J Mol Sci       Date:  2021-05-03       Impact factor: 5.923

7.  CXCL13 promotes isotype-switched B cell accumulation to the central nervous system during viral encephalomyelitis.

Authors:  Timothy W Phares; Krista D DiSano; Stephen A Stohlman; Benjamin M Segal; Cornelia C Bergmann
Journal:  Brain Behav Immun       Date:  2016-01-18       Impact factor: 7.217

8.  Activated GL7+ B cells are maintained within the inflamed CNS in the absence of follicle formation during viral encephalomyelitis.

Authors:  Krista D DiSano; Stephen A Stohlman; Cornelia C Bergmann
Journal:  Brain Behav Immun       Date:  2016-09-19       Impact factor: 7.217

9.  Dynamics of Virus-Specific Memory B Cells and Plasmablasts following Viral Infection of the Central Nervous System.

Authors:  Jeffrey R Atkinson; Mihyun Hwang; Angel Reyes-Rodriguez; Cornelia C Bergmann
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 10.  Why do SARS-CoV-2 NSPs rush to the ER?

Authors:  Maryline Santerre; Sterling P Arjona; Charles Ns Allen; Natalia Shcherbik; Bassel E Sawaya
Journal:  J Neurol       Date:  2020-09-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.